SCHEMBL2919562

SCHEMBL2919562

Nc1cc(CO)c2cc[nH]c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 1/20 0.37
CHEK1 O14757 1/20 0.34
HTR6 P50406 3/20 0.33
HTR2C P28335 2/20 0.33
HASPIN Q8TF76 1/20 0.33
AURKA O14965 1/20 0.33
TPX2 Q9ULW0 1/20 0.33
IMPDH2 P12268 1/20 0.33
TYMS P04818 1/20 0.32
ADRB1 P08588 1/20 0.31
HTR1A P08908 1/20 0.31
ADRA2A P08913 1/20 0.31
SLC6A2 P23975 1/20 0.31
HTR1D P28221 1/20 0.31
HTR1B P28222 1/20 0.31
HTR2A P28223 1/20 0.31
HTR1E P28566 1/20 0.31
SLC6A4 P31645 1/20 0.31
HTR7 P34969 1/20 0.31
HTR2B P41595 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19329521 0.81 HTR6 (0.35) HTR6HTR2CADRB1HTR1AADRA2A
Hydrochloric Acid SCHEMBL2913110 0.78 HPGD (0.41) HTR6AURKATPX2ALDH1A1PARP1
SCHEMBL30805086 0.78 GPR84 (0.44) RHEBCHEK1HASPINAURKATPX2
SCHEMBL8114974 0.78 CHEK1 (0.43) RHEBCHEK1HTR6HASPINAURKA
SCHEMBL8127712 0.78 HTR2A (0.40) RHEBCHEK1HASPINAURKATPX2
SCHEMBL29714416 0.77 KDM4E (0.44) HTR6HTR2CHTR1ASLC6A2HTR1D
SCHEMBL22778067 0.77 KDM4E (0.44) HTR6HTR2CHTR1ASLC6A2HTR1D
SCHEMBL22777982 0.75 HTR2A (0.36) HTR6HTR2CHTR1AHTR1DHTR1B
SCHEMBL22778021 0.75 HTR1A (0.50) CHEK1HTR6HTR2CHTR1AADRA2A
SCHEMBL29714369 0.75 HTR1A (0.50) CHEK1HTR6HTR2CHTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017153952-A1 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-09-14 WO disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K RHEB 2069/4885CHEK1 131/4885HTR6 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.